Savara (NSDQ:SVRA) announced today that it priced an underwritten public offering of common stock at approximately $113 million.
Austin, Texas–based Savara — an orphan lung disease treatment company with an inhaled formulation of recombinant human GM-CSF — is offering nearly 45.8 million shares of its common stock to the public at a price of $1.45 per share, according to a news release.
Get the full story at our sister site, Drug Delivery Business News.